Patient Medication Information: uses, side effects, how to take - Mresvia
What mRESVIA is used for:
mRESVIA is a vaccine to help protect you against lower respiratory tract disease (LRTD) caused by RSV.
mRESVIA is for people 60 years of age and older, and also for people 18 through 59 years of age who are at increased risk for RSV (people with medical conditions which include, but are not limited to, diabetes or with diseases affecting the lungs, and heart).
How mRESVIA works:
mRESVIA works by causing the body to produce its own protection (antibodies) against RSV. mRESVIA uses a molecule called messenger ribonucleic acid (mRNA, the genetic code for a piece of the virus) to deliver the set of instructions that cells in your body can use to make antibodies to help fight the virus that causes RSV.
As mRESVIA does not contain the RSV virus, it cannot cause an RSV infection.
As with all vaccines, mRESVIA may not fully protect all people who receive the vaccine.
The ingredients in mRESVIA are:
Medicinal ingredient(s): one 0.5 mL dose of mRESVIA contains 50 micrograms of mRNA encoding RSV glycoprotein F stabilized in the prefusion conformation
Non-medicinal ingredients:
- acetic acid
- cholesterol
- DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine)
- SM-102 (Heptadecan-9-yl 8-((2-hydroxyethyl) (6-oxo-6-(undecyloxy) hexyl) amino) octanoate)
- PEG2000-DMG (1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000)
- sodium acetate trihydrate
- sucrose
- trometamol
- trometamol hydrochloride
- water for injection
mRESVIA comes in the following dosage form(s):
mRESVIA is available as a dispersion for intramuscular injection. mRESVIA comes in a single-dose (0.5 mL) pre-filled syringe.
Do not receive mRESVIA if:
You are allergic (hypersensitive) to any of the ingredients contained in mRESVIA (see The ingredients in mRESVIA are). Signs of an allergic reaction may include itchy skin rash, shortness of breath and swelling of the face or tongue.
mRESVIA is contraindicated in children less than 2 years of age due to an increased risk of severe and life-threatening RSV-enhanced respiratory disease reported in infants immunized between 5 to less than 8 months of age during a clinical study. The risk of RSV-enhanced respiratory disease is not applicable to adults.
To help avoid side effects and ensure proper use, talk to your healthcare professional before you take mRESVIA. Talk about any health conditions or problems you may have, including if you:
- have a severe infection with a high temperature. In these cases, the vaccination may be postponed until recovery. A minor infection such as a cold, including mild fever, should not be a problem, tell your healthcare professional first
- had a severe allergic reaction after receiving a previous dose of any vaccine, including those against RSV infection
- are immunocompromised or are on a medicine that affects your immune system
- are pregnant or plan to become pregnant
- are breastfeeding
- have ever fainted in association with an injection or before receiving any needle injection
- have a bleeding disorder or are on a blood thinner
Other warnings you should know about:
Do not drive or use machines if you are feeling unwell.
Pediatrics (< 18 years of age):
- mRESVIA is not indicated for use in infants, children and adolescents under 18 years old.
- mRESVIA is contraindicated for use in children younger than 2 years of age due to an increased risk of RSV enhanced respiratory disease.
Pregnancy and breast-feeding:
- There is no information on the use of mRESVIA in pregnant or breast-feeding women.
- mRESVIA is not recommended for use in pregnancy.
Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.
There is limited information on the use of mRESVIA with other vaccines. Tell your healthcare professional if you have recently received any other vaccine.
How to take mRESVIA:
Your doctor, pharmacist or nurse will inject the vaccine into a muscle.
If mRESVIA is given at the same time as another vaccine, a different injection site will be used for each vaccine.
Usual dose:
mRESVIA is given as a single dose of 0.5 mL as an injection.
Overdose:
| If you think you, or a person you are caring for, have taken too much mRESVIA, contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada’s toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms. |
|---|
Possible side effects from using mRESVIA:
Like all vaccines, mRESVIA can cause side effects, although not everyone gets them.
The following side effects may occur after receiving mRESVIA. Most of these side effects are mild and do not last long. These are not all the possible side effects you may have when taking mRESVIA.
Very common (these may occur with more than 1 in 10 doses of the vaccine):
- pain at the injection site
- fatigue
- chills
- headache
- swelling of lymph nodes
- muscle pain and joint pain
Common (these may occur with up to 1 in 10 doses of the vaccine):
- redness and swelling at the injection site
- swelling of lymph nodes
- fever
- nausea and vomiting
If you have a troublesome symptom or side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.
Reporting suspected side effects for vaccines For the general public: Should you experience a side effect following immunization, please report it to your healthcare professional. Should you require information related to the management of the side effect, please contact your healthcare professional. The Public Health Agency of Canada (PHAC), Health Canada (HC), and Moderna Biopharma Canada Corp. cannot provide medical advice. For healthcare professionals: If a patient experiences a side effect following immunization, please complete the Adverse Events Following Immunization (AEFI) Form appropriate for your province/territory (Reporting Adverse Events Following Immunization (AEFI) in Canada) and send it to your local Health Unit. |
|---|
Storage:
Your doctor or pharmacist is responsible for storing, supplying and administering mRESVIA, as well as disposing of any unused product correctly.
Keep out of reach and sight of children.
If you want more information about mRESVIA:
- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website (Drug Product Database: Access the database); the manufacturer’s website www.modernatx.com/en-CA; or by calling 1-866-MODERNA [1-866-663-3762].
Date of Authorization: 2026-08-19
©2026 ModernaTX, Inc. All rights reserved. mRESVIA is a trademark of ModernaTX, Inc.